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Epidermal Growth Factor Receptor-Related Tumor Markers
and Clinical Outcomes with Erlotinib in Non-small Cell
Lung Cancer
An Analysis of Patients from German Centers in the TRUST Study
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Eckart Laack, MD, Werner Digel, MD,¶ Wolf-Ru¨diger Guschall, MD,# Andreas Franke, MD,**
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Introduction: Relationships between clinical outcomes and epider-
mal growth factor receptor (EGFR)-related tumor markers were
investigated in patients with advanced non-small cell lung cancer.
Methods: Patients with stage IIIB/IV non-small cell lung cancer (0–2
prior regimens) received erlotinib (150 mg PO per day). Response and
survival were evaluated, and tumor samples were assessed by immu-
nohistochemistry (EGFR, phosphorylated mitogen-activated protein
kinase, and phosphorylated AKT protein expression), fluorescence in
situ hybridization (FISH; EGFR gene copy number), and DNA se-
quencing (EGFR, KRAS gene mutations).
Results: Among 311 patients, 8% had a complete/partial response;
the disease control rate was 66%. Median Overall survival (OS) was
6.1 months; 1-year survival rate was 27.2%. Two of 4 patients with
EGFR mutations had tumor responses, versus 2/68 with wild-type
EGFR (p  0.014). Progression-free survival (PFS) (HR  0.31)
and OS (HR  0.33) were significantly prolonged in patients with
EGFR mutations. Response rate was significantly higher in patients
with EGFR FISH-positive (17%) than FISH-negative tumors (6%),
and both PFS (HR  0.58) and OS (HR  0.63) significantly
favored patients with EGFR FISH-positive tumors; median OS was
8.6 months in the EGFR FISH-positive group. None of 17 patients
with a KRAS mutation had a tumor response, but the impact of KRAS
mutation status on survival outcomes was of borderline statistical
significance. Neither phosphorylated mitogen-activated protein ki-
nase nor phosphorylated AKT immunohistochemistry status had a
significant effect on PFS and OS with erlotinib.
Conclusions: The presence of EGFR mutations and EGFR FISH-
positive tumors may predispose patients to achieving better outcomes
on erlotinib, but may have a beneficial impact on prognosis (irrespective
of treatment). Prospective, placebo-controlled studies are needed to
determine the predictive value of the putative biomarkers.
Key Words: Erlotinib, Non-small cell lung cancer, Epidermal
growth factor receptor (EGFR), EGFR mutations, EGFR gene copy
number.
(J Thorac Oncol. 2008;3: 1446–1453)
Intracellular signaling activated by the epidermal growthfactor receptor (EGFR) plays a role in tumor growth and
progression in many cancers1,2 and EGFR overexpression
occurs in up to 80% of non-small cell lung cancers
(NSCLC).3,4 Erlotinib is a selective inhibitor of EGFR ty-
rosine kinase activity,5 demonstrated to significantly prolong
survival versus placebo in patients with relapsed NSCLC.6
There is currently much interest in determining which
patients benefit most from EGFR tyrosine kinase inhibitor
(TKI) therapy, and identifying tumor markers that predict
clinical outcomes. The findings to date are inconclusive, due
to the small number of samples analyzed, and the retrospec-
tive nature of most studies.7,8 One of the largest controlled
datasets on potential biomarkers for erlotinib comes from the
BR.21 trial.9–11 While there were trends in the data, multi-
variate analyses suggested that survival was not significantly
influenced by EGFR expression, the number of EGFR gene
copies, or the presence of EGFR mutations.
This paper describes analyses of relationships between
clinical benefits and putative tumor markers measured in
samples from patients participating in Tarceva Lung Cancer
Survival Treatment (TRUST), a large, open-label trial of
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erlotinib (7043 patients in 52 countries). The analysis was
limited to patients in German centers. The markers examined
were EGFR expression; EGFR gene copy number; EGFR
mutations; KRAS mutations; and expression of phosphory-
lated AKT (pAKT) and phosphorylated mitogen-activated
protein kinase (pMAPK). The second objective was to eval-
uate relationships between different markers.
PATIENTS AND METHODS
Trial Design
The trial is an open-label single-arm study of erlotinib
in patients with advanced (inoperable stage III B or IV)
NSCLC who failed or were not medically suitable for stan-
dard first-line chemotherapy. This analysis relates to patients
registered in Germany, who received at least one dose of
erlotinib, and for whom a tumor sample was available.
Patients
Patients were eligible if they met the following criteria:
18 years with histologically or cytologically confirmed,
unresectable, stage III B/IV NSCLC; Eastern Cooperative
Oncology Group performance status 0–3; 1/2 prior courses of
standard chemotherapy or radiotherapy, or were unsuitable
for such treatment; at least 3 to 4 weeks since last treatment
(surgery within 4 weeks allowed, if fully recovered); full
recovery from toxicities due to prior therapy; adequate he-
matological, renal, and hepatic function; life expectancy 12
weeks; negative pregnancy test for women of child-bearing
potential.
Notable exclusion criteria were: evidence of unstable
systemic disease; prior treatment with anti-EGFR agents;
previous malignancies (last 5 years, other than successful
treatment for cervical carcinoma/skin cancer); untreated brain
metastases or spinal cord compression; significant ophthal-
mologic abnormalities (e.g., severe dry eye syndrome, kera-
toconjunctivitis sicca, Sjo¨gren syndrome, severe exposure
keratitis).
Informed consent was obtained, and local or regional
ethical committee approval was received by all centers. The
trial was conducted in accordance with the Declaration of
Helsinki and its subsequent amendments, and with Good
Clinical Practice guidelines.
Drug Administration
All patients received erlotinib 150 mg PO per day.
(Tarceva; F. Hoffmann-La Roche, Basel, Switzerland). Treat-
ment continued until unacceptable toxicity, disease progression
or death, or withdrawal. Dose escalation was not permitted.
Dose interruption/reduction was permitted for treatment-related
adverse events. Reescalation was not permitted, except after
erlotinib-related rash.
Clinical Assessments
Tumor response was assessed using Response Evalua-
tion Criteria in Solid Tumors,12 at least every 2 months.
Responses were confirmed after 4 weeks. Overall survival
(OS) and progression-free survival (PFS) were calculated
from date of randomization to date of death/date of disease
progression or death, respectively. Clinical assessments were
at baseline and then every 4 weeks.
Biomarker Analyses
Tumor samples were collected at initial diagnosis or
before treatment (sites were asked to provide formalin-fixed,
paraffin-embedded tissue blocks or 10 unstained slides).
Availability of a tissue sample was not mandatory; patients’
written consent was required for use of tumor samples. Gene
sequencing was performed at the Roche Center for Medical
Genomics (Basel, Switzerland), other histopathological and
molecular analyses at TARGOS Molecular Pathology GmbH,
Kassel, Germany, using technically validated, optimized and
standardized assays.
EGFR and KRAS Mutation Analyses
Manual microdissection or laser capture microdissec-
tion was performed on formalin-fixed paraffin-embedded tis-
sue sections (to harvest 5000 tumor cells and increase
sample DNA content). DNA lysates were prepared from
microdissected tissue. Amplifications of EGFR exons 18–21
and KRAS exon 2 and 3 were performed using nested prim-
ers.13 All polymerase chain reactions (PCRs) were performed
with HotStarTaq (Qiagen); 95°C  15 minutes; 95°C  1
minute, 60°C  30 seconds, 72°C  30 seconds, for 30
cycles, then 72°C for 5 minutes, 20 L reactions. Templates
were treated with uracil-N-glycosylase to prevent artifacts.
PCR products were purified with PCR96 Cleanup Plates
(Millipore). Sequencing reactions were performed using Ap-
plied Biosystems Version 3.1 Big Dye Terminator chemistry,
and analyzed on an Applied Biosystems 3730 Sequencer.
PCR products were sequenced in sense and antisense direc-
tions. Only the most common EGFR gene mutations were
evaluated (E746-A750 deletion in exon 19; L858R in exon
21). Mutations in codons 12 and 13 of exon 2, and codon 61
of exon 3 of KRAS were also analyzed. Samples were classed
as ‘mutated’ (1 mutation detected), ‘wild-type’ (no muta-
tions detected), or ‘indeterminate’ (failed analysis in 1
locus and ‘wild-type’ in the other locus).
Immunohistochemistry and Fluorescence In
Situ Hybridization Analyses
EGFR protein expression was assessed using the EGFR
PharmDx immunohistochemistry (IHC) kit (#K1492, Dako,
Glostrup, Denmark). Samples were rated EGFR-positive if
membranous staining was observed in either 10% of tumor
cells or in any tumor cells (‘any staining’ cutoff). pMAPK
and pAKT were assessed using IHC with the ‘Phospho-
p44/42 MAPK’ antibody (#4376, rabbit clone 2OG11, Cell
Signaling, Danvers) and the rabbit monoclonal ‘phospho-
AKT (Ser473)’ antibody (#3787, clone 736E11, Cell Signal-
ing, Danvers), respectively. Cytoplasmic staining of pMAPK
and nuclear staining of pAKT were quantified using H-scores
calculated from staining intensity (0–3) and percentage of
stained cells (0–100%). The cutoff for positivity was H-score
200. EGFR gene copy number was assessed by fluores-
cence in situ hybridization (FISH) using commercial probes
(LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe
#32–191053, Abbott/Vysis, Des Plaines). Samples with
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high gene copy number (high polysomy/gene amplification)
were classed as FISH-positive.14
Statistics
For binary variables, values were set to 0 (female,
squamous-cell carcinoma, never-smoker, IHC/FISH-nega-
tive) or 1 (male, adenocarcinoma, current/former smoker,
positive IHC/FISH status). For response-based clinical out-
comes, ordinal values set were: 0  progressive disease; 1 
stable disease (SD) 120 days; 2  SD 120 to 180 days; 3 
SD 180 days; 4  partial response (PR); 5  complete
response (CR). FISH strata (1–6) were considered ordinal
variables and IHC H-scores were considered metric variables.
Positive/negative test status is inherently binary.
Differences in response rates and PFS/OS according to
biomarker status were tested with Fisher’s exact test and the
log-rank test, respectively. Associations between variables
were assessed using nonparametric tests: Spearman’s rank
correlation for metric or ordinal variables; Wilcoxon rank
sum test for metric/ordinal versus binary variables (the rele-
vant Mann-Whitney MW score indicating the strength of
association); Fisher’s exact test for binary variables (the
Phi-coefficient indicating the strength of association).
RESULTS
Patients
The intent-to-treat population (n  393) comprised all
registered patients from Germany with a tumor tissue sample
submitted for analysis, who received at least one dose of
erlotinib, for whom clinical data was available by the cutoff
date (June 21, 2007). Table 1 summarizes the demographic
and baseline clinical/tumor characteristics. The majority of
patients (79%) had stage IV NSCLC; 77% received erlotinib
as second- or third-line therapy.
Efficacy
Clinical information was not available for all patients.
Tumor response was available for 311 of 393 patients (17 not
evaluable; 65 no data). The overall response rate was 7.9% (26
of 328); 4 CRs and 22 PRs. Fifty-eight percent (189 of 328) had
SD. The disease control rate (CR  PR  SD) was 66%.
Survival data were available for 392 of 393 patients. Median
PFS was 2.33 months (95% confidence interval CI, 2.00–
2.96). Median OS was 6.11 months (95% CI, 5.09–7.29: Figure
1); 1-year survival was 26.2% (95% CI, 21.6–30.7).
Relationships Between Biomarker Status and
Clinical Outcomes with Erlotinib
Not all biomarker measurements were available for
every patient (Table 1), due to inadequacy/poor quality of
tissue and assay failures. Table 2 shows response and survival
outcomes on erlotinib according to marker status. Two of 4
patients with EGFR mutations had tumor responses (50%)
versus 2 of 68 with wild-type EGFR (3%; p  0.014).
Response rates were significantly higher in patients with
EGFR FISH-positive (17%) than FISH-negative tumors
(6%), and those with pAKT IHC-positive (21%) than IHC-
negative tumors (5%).
Using the positivity criterion for EGFR IHC of 10%
membranous staining, PFS and OS both favored patients with
EGFR IHC-positive tumors (not shown), but neither differ-
ence was statistically significant (Table 2). Using the ‘any-
staining’ criterion the differences in PFS and OS were more
marked, but did not reach statistical significance.
PFS and OS both significantly favored patients with
EGFR FISH-positive tumors (Table 2 and Figure 2). Median
OS was 8.6 and 6.1 months for the FISH-positive and
FISH-negative groups, respectively. EGFR FISH status was
significantly correlated with response-based clinical out-
TABLE 1. Demographic and Baseline Clinical Characteristicsa (n  393)
n %
Age Years: median (range) 65 (31–90)
Gender Male/female 232/161 59/41
Ethnic origin Caucasian/oriental/no data 389/3/1 99/11
Histology Adenocarcinoma/squamous cell carcinoma/other 200/124/69 51/32/18
Smoking status Never-smoker/former or current smoker/no data 96/296/1 24/75/1
ECOG PS 0/1/2/3 88/200/84/21 22/51/21/5
Stage IIIB/IV 81/312 21/79
Line of therapy 1st/2nd/3rd/other/no data 75/158/147/12/1 19/40/37/3/1
Tumor characteristics % positive
EGFR IHC (10%) Positive tests/total tests 236/293 81
EGFR IHC (any staining) Positive tests/total tests 257/293 88
EGFR FISH Positive tests/total tests 49/208 24
EGFR mutations Mutation/wild-type/indeterminate/total tests 6/86/103/195 7b
KRAS mutations Mutation/wild-type/indeterminate/total tests 17/97/81/195 15b
pMAPK IHC Positive tests/total tests 48/195 25
pAKT IHC Positive tests/total tests 54/192 28
a For patients with biomarker data.
b % mutation rate  mutations/(mutations  wild-type)  100.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; IHC, immunohisto-
chemistry; FISH, fluorescence in situ hybridization; pMAPK, phosphorylated mitogen-activated protein kinase; pAKT, phosphorylated AKT.
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comes (as defined in the methods section; MW score  0.66;
p  0.001, n  161).
Sixty-one patients with data for both EGFR IHC and
EGFR FISH also had response data. Seven had responses (2
CR, 5 PR), and all 7 were both IHC- and FISH-positive. Of
the 54 patients with SD/PD, 31 were both IHC- and FISH-
positive, while 23 tested positive for one marker or neither
(p  0.04, Fisher’s exact test). There was a significant
relationship between IHC/FISH ‘double-positive’ status and
response-based clinical outcomes (MW score  0.73, p 
0.002, n  61).
EGFR mutations were detected in 6 of 92 patients
(7%); L858R in four, and the E746-A750 deletion in two.
One of these patients had CR, one PR, and 2 SD as best
response (1 not evaluable; 1 no data). Patients with mutations
had significantly longer PFS (hazard ratio HR  0.31) and
OS (HR  0.33) than those with wild-type or indeterminate
genes (Table 2, Figure 2) Five of the six tumors with EGFR
mutations were adenocarcinomas; all were EGFR IHC-posi-
tive (four were EGFR FISH-positive). Four patients with
mutations were never-smokers, and four were women. EGFR
and KRAS mutations were mutually exclusive.
Seventeen patients (15%) had KRAS mutations; 15 at
codon 12 (G12X), one at codon 13 (G13X) and one at codon
61 (Q61X). None of the patients had a response to erlotinib,
but 6 had SD. The impact of KRAS mutation status on PFS
and OS was of borderline statistical significance (Table 2 and
Figure 2). Of the 17 patients with KRAS mutations, 16 were
smokers, and 12 were men. None of the tumors were EGFR
FISH-positive, 13 were EGFR IHC-positive and 15 were
nonsquamous tumors.
Patients testing positive for pMAPK IHC had shorter
PFS and OS than those with negative pMAPK IHC tests
(Figure 3), but the difference in PFS was not significant and
the difference in OS was of borderline significance (Table 2).




(95% CI) pc Positive/Negative
PFS OS
nb % nb % HR pd HR pd
EGFR IHC
(10%)
18/191 9.4 2/42 4.8 2.08 (0.46–9.34) 0.542 231/57 0.79 (0.59–1.06) 0.120 0.84 (0.61–1.14) 0.254
EGFR IHC
(any)
19/208 9.1 1/25 4.0 2.41 (0.31–18.83) 0.705 252/36 0.73 (0.51–1.04) 0.081 0.73 (0.51–1.06) 0.097
EGFR FISH 7/41 17.1 7/120 5.8 3.32 (1.09–10.14) 0.048 49/157 0.58 (0.42–0.82) 0.002 0.63 (0.43–0.91) 0.012
EGFR mutation 2/4 50.0 2/68 2.9 33.0 (2.96–370.4)e 0.014 6/85f 0.31 (0.13–0.78)e 0.009e 0.33 (0.12–0.91)e 0.025e
KRAS mutation 0/11 0 7/78 9.0 na 0.590 17/96f 1.56 (0.92–2.65)e 0.094e 1.64 (0.97–2.80)e 0.064e
pMAPK IHCg 2/33 6.1 15/120 12.5 0.45 (0.10–2.08) 0.368 47/146 1.26 (0.90–1.77) 0.183 1.39 (0.98–1.99) 0.067
pAKT IHCg 9/42 21.4 5/110 4.5 5.73 (1.79–18.28) 0.003 53/137 0.80 (0.57–1.11) 0.184 0.98 (0.70–1.37) 0.896
a For patients with both biomarker data and response/survival data.
b Responders (CR  PR)/total.
c Fisher’s exact test.
d Log-rank test.
e Excludes patients with indeterminate mutation status.
f Mutation/wild-type (101 indeterminate results for EGFR; 79 indeterminate results for KRAS).
g H-Score 200.
PFS, progression-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; FISH,
fluorescence in situ hybridization; na, not applicable; pMAPK, phosphorylated mitogen-activated protein kinase; pAKT, phosphorylated AKT.
FIGURE 1. Progression-free (A) and overall survival (B) dur-
ing treatment with erlotinib.
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FIGURE 2. Survival outcomes according to tumor marker status. Epidermal growth factor receptor (EGFR), fluorescence in
situ hybridization (FISH) (A), EGFR mutation analysis (B) and KRAS mutation analysis (C).
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Median OS was 4.2 and 7.2 months in pMAPK IHC-positive
and IHC-negative patients, respectively. pAKT IHC status
had no detectable effect on PFS or OS (Table 2).
Relationship Between Smoking Status and
Clinical Outcome
Never-smokers were more likely than former/current
smokers to benefit; clinical outcome and smoking status was
significantly correlated (MW score  0.34, p  0.0001).
There were more women among the never-smokers (82%)
than the smokers (28%), and this may have contributed to the
difference in clinical outcome. A separate analysis found no
significant association between gender and clinical outcome
(male: MW score  0.44, p 0.076, n 311). Also, 92% of
patients with squamous-cell carcinoma were smokers, versus
66% of those with adenocarcinoma (Fisher’s exact test: p 
0.001; Phi  0.29; n  340).
Significant differences in pAKT protein expression
were observed between former/current and never-smokers.
Forty-four percent of never-smokers were pAKT IHC-posi-
tive, versus 23% of smokers (Fisher’s exact test; p  0.01).
Relationship Between Skin Toxicity and Clinical
Outcome
Of 392 patients with data available, 267 (68%) experi-
enced rash, with the majority of these cases (218 patients;
82%) being grade 1 or 2. Both PFS and OS were significantly
longer in patients who obtained grade 2 rash, compared
with those who had grade 1 or no rash: median PFS 19.5
weeks versus 12.4 weeks, respectively (HR  0.70, log-rank
p  0.007); median OS 9.7 weeks versus 5.9 weeks, respec-
tively (HR  0.68, log-rank p  0.005).
Relationships Between Putative Biomarkers
The percentage of cells with EGFR IHC membrane
staining increased with increasing Cappuzzo EGFR FISH
stratum (  0.25, p  0.001, n  208, Spearman’s rank
correlation). This was also apparent when staining intensity
was quantified using H-scores. Ninety-two percent (45 of 49)
of EGFR FISH-positive tumors were EGFR IHC-positive
(‘any staining’ cutoff; p  0.05, Fisher’s exact test), while
90% (36 of 40) of EGFR IHC-negative tumors were EGFR
FISH-negative (p  0.05, Fisher’s exact test). EGFR FISH
and IHC status were concordant in 81 of 208 patients (39%).
Thirty-two percent (48 of 151) of EGFR IHC-positive
tumors were pAKT-positive and 25% were pMAPK-positive.
No relationships were identified between pMAPK status and
other markers (data not shown).
Relationships Between Tumor Histology and
Biomarker Status
EGFR IHC-positive status was more common in squa-
mous-cell carcinomas (89%; 84 of 94) than adenocarcinomas
(78%; 125 of 161; p  0.05, Fisher’s exact test). The
percentage of membranous staining was also greater in squa-
mous cell carcinomas (MW score  0.67; p  0.0001; n 
255). Both adenocarcinomas (55%) and squamous-cell car-
cinomas (67%) were mainly EGFR IHC-positive and EGFR
FISH-negative (Figure 4), but 21% of adenocarcinomas were
EGFR IHC-negative and EGFR FISH-negative, versus 11%
of squamous-cell carcinomas.
DISCUSSION
Findings from the BR.21 study suggested that putative
biomarkers for outcomes with erlotinib were worthy of fur-
ther investigation.9–11 In this trial, we examined the relation-
ships between certain previously reported candidate markers
and clinical outcomes in patients receiving open-label treat-
ment with erlotinib. We also examined two other components
of EGFR-linked signaling, pAKT and pMAPK, as potential
markers for outcomes with erlotinib in patients with NSCLC.
The outcomes with erlotinib in this study are generally
consistent with those from the phase III erlotinib study.6 The
response rates were similar (7.9 and 8.9%, respectively), but
here the disease control rate was somewhat higher (66%
versus 45%). PFS and OS (2.3 and 6.1 months) were very
similar to those in the double-blind setting (2.2 and 6.7
months, respectively).
As previously reported,6 the response rate to erlotinib
favored patients with EGFR mutations (but based on a small
FIGURE 3. Progression-free survival (PFS) (A) and overall sur-
vival (OS) (B) according to phosphorylated mitogen-activated
protein kinase (pMAPK) status (immunohistochemistry).
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number of patients) and, less markedly, in those with high
EGFR gene copy number. According to a meta-analysis
based on 1335 patients, the response rate to TKIs in patients
with EGFR mutations is approximately 70%, versus 10% in
those with wild-type EGFR,15 but the proportion with clinical
benefit is generally greater than the proportion with EGFR
gene mutations.6,16,17 In the current trial, 66% of patients had
a clinical benefit, but only 7% had EGFR mutations.
Although patients with EGFR mutations had longer
PFS and OS than those with wild-type EGFR or indetermi-
nate status, there is currently no general agreement about the
predictive value of EGFR mutations for survival with erlo-
tinib. Patients with EGFR mutations may have prolonged
survival, regardless of the treatment received.18 Given the
uncontrolled nature of the present study, and the small num-
bers of patients possessing an EGFR mutation, we are unable
to determine whether the survival benefit in patients with
EGFR mutations was treatment-related. In BR.21, EGFR
mutation status was neither prognostic nor predictive.11 To
provide more definitive answers, it will be necessary to
conduct large randomized controlled studies with prospective
assessment of EGFR mutation status. Another approach cur-
rently being investigated by the Spanish Lung Cancer Group
is the use of erlotinib as a first-line treatment for patients with
EGFR mutations.
Our analysis indicates that patients with EGFR high poly-
somy or gene amplification had a significantly higher response
rate to erlotinib, and longer OS and PFS. Shepherd et al.11
reported that EGFR FISH-positive status was both prognostic
for poorer survival (p  0.005) and predictive for survival
benefit with erlotinib (p  0.009). In a randomized, open-label
trial (IRESSA non-small cell lung cancer trial evaluating re-
sponse and survival against Taxofere [INTEREST]) there was
no notable difference in survival between gefitinib and
docetaxel in any biomarker-defined subgroup, including
patients classified by EGFR FISH status.19 However, in
INTEREST, the control group received docetaxel, but in
BR.21 the control group received placebo, so the two
studies are not directly comparable. In a randomized pla-
cebo-controlled trial of relapsed NSCLC, the effect of
gefitinib on survival in EGFR FISH-positive patients was
of borderline significance (HR  0.61, p  0.067), but no
notable effect was observed in FISH-negative patients
(HR  1.16, p  0.417).20
In this study, no patients with KRAS mutations had an
objective tumor response. This was not surprising, as the
presence of KRAS mutations seems to be a negative prognos-
tic factor in NSCLC.21,22 The hazard ratios for the effect of
KRAS status on PFS and OS were high, but were not statis-
tically significant (due to the limited number of samples).
Among the 6 patients with KRAS mutations who had SD as
best response, 4 had a grade 2 rash and PFS was between 3
and 8 months, approximately. In BR.21, the response rate was
5% in patients with KRAS mutations and 10% in those with
the wild-type gene. The HRs for survival with erlotinib
versus placebo were 1.67 and 0.69 respectively, but the
difference was not significant (pinteraction  0.09).11 Further
studies are needed to give a more definitive answer to the
question of whether patients with KRAS mutations can derive
survival benefit from erlotinib.
pMAPK-positive status may be a negative prognostic
factor in NSCLC,23,24 but, to our knowledge, this is the first
study to examine the effect of pMAPK-IHC and pAKT status
on outcomes with erlotinib in NSCLC. Patients with pMAPK
IHC-positive tumors had shorter PFS and OS than those with
pMAPK IHC-negative tumors, but the differences were not
marked. The response rate on erlotinib favored patients with
pAKT IHC-positive versus IHC-negative tumors, but this
was not reflected by differences in PFS or OS.
Current data do not support selection of patients for
treatment with erlotinib on the basis of tumor molecular
characteristics.7 Emerging data from ongoing studies, partic-
ularly the Sequential Tarceva in unresectable NSCLC (SAT-
URN) trial, should provide further clarification. In BR.21,
FIGURE 4. Epidermal growth factor receptor (EGFR), im-
munohistochemistry (IHC) and fluorescence in situ hybridiza-
tion (FISH) status in adenocarcinomas (A) and squamous cell
carcinomas (B).
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most types of patients obtained a therapeutic benefit with
erlotinib, irrespective of clinical or tumor molecular charac-
teristics.6,11 These findings were confirmed in the TRUST
study, in which the clinical benefit from erlotinib was ob-
served in a broad range of patient subgroups based on clinical
characteristics.25,26 Whether patients who are likely to benefit
most from EGFR TKI therapy can be reliably identified is
open to question. The aforementioned SATURN trial, a large,
randomized, controlled study examining candidate biomark-
ers in a prospective manner, in patients receiving mainte-
nance erlotinib following first-line chemotherapy, may help
to provide a definitive answer.
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